Saffron Extract (Affron® / Satiereal®)

The world's most expensive spice with clinical data rivaling first-line antidepressants.

Standardized saffron extracts (particularly Affron® and Satiereal®) have RCT evidence for depression, mood, ADHD, and appetite/weight management. Premium pricing, strong differentiation, and head-to-head data against SSRIs make this an unusually defensible botanical position.

Saffron (Crocus sativus) is the world's most expensive spice by weight, harvested by hand from the stigmas of crocus flowers. The supplement-grade extracts that have built the modern category are concentrated and standardized to the active compounds safranal, crocin, and crocetin. The two branded extracts that dominate the clinical and consumer market are Affron® (Pharmactive Biotech, 28 mg standardized to ≥3.5% Lepticrosalides®) and Satiereal® (PharmaFood/Nexira, 176.5 mg standardized for satiety positioning).

The clinical evidence base is exceptional for a botanical. Multiple RCTs and meta-analyses show saffron extracts producing antidepressant effects comparable to fluoxetine and imipramine in mild-to-moderate depression. There's strong RCT data in pediatric and adult ADHD with saffron matching methylphenidate in small head-to-head trials. Appetite and weight-management trials with Satiereal show modest but consistent reductions in snacking and caloric intake. The breadth and quality of the human data is rare for a botanical at this scale.

For founders, saffron occupies an unusual position: premium-priced raw material (often $3,000–$6,000/kg for clinical-grade extract vs $100–$300/kg for generic herbal extracts), strong clinical differentiation, and a consumer narrative that doesn't depend on viral moments. The brands winning here are clinical-credibility plays. Practitioner-recommended mood support, premium DTC wellness, and stress-and-mood positioning. Mass retail and budget tiers don't work because the unit economics don't allow effective dosing.

Why Brands Choose Saffron Extract (Affron® / Satiereal®)

Botanical with antidepressant-comparable trial data

Multiple RCTs match saffron to fluoxetine and imipramine in mild-to-moderate depression. No other herbal mood active has this depth of head-to-head pharmaceutical data.

Cross-category positioning supports a product line

Mood, ADHD, appetite, eye health, and even premenstrual symptom support. One branded extract anchors multiple SKUs.

Premium pricing tolerance

Saffron's price point and clinical credibility support DTC subscriptions and clinical-channel pricing well above commodity herbal tiers.

Formulation Notes

Working with Saffron Extract (Affron® / Satiereal®)

  • Affron® standard dose: 28 mg/day, standardized to ≥3.5% Lepticrosalides® (the proprietary safranal/crocin profile).
  • Satiereal® standard dose: 176.5 mg/day, two divided doses with meals for the appetite-management positioning.
  • Both branded extracts ship with clinical citation rights and marketing collateral. Worth the licensing premium for the credibility story.
  • Encapsulation is preferred. Saffron is bitter and has a strong floral aroma that resists masking in powders and gummies.
  • Pair with omega-3 or curcumin in mood-positioning formulas; with chromium and green tea in appetite-positioning formulas.
  • Adulteration is a long-standing issue with raw saffron. Branded extracts include authenticity testing as part of their value proposition.

Dosage Guidance

Mood/depression positioning (Affron): 28 mg/day. Appetite/weight positioning (Satiereal): 176.5 mg/day in 2 divided doses. ADHD and pediatric protocols use 20–30 mg/day under clinical supervision.

Delivery Forms

CapsuleTabletSoftgel

Considerations

  • Direct head-to-head antidepressant trial data is a marketing strength and a regulatory landmine. Disease-treatment claim language must be avoided.
  • Doses above 1.5 g/day of saffron extract can produce nausea, headache, and GI upset. Stay within trial-supported ranges (≤200 mg/day) for consumer products.
  • Adulteration with safflower, marigold, or synthetic dyes is documented in commodity saffron supply. Use only audited branded extracts with authenticity testing.
  • Pregnancy contraindication. High-dose saffron has historic abortifacient associations. Required warnings vary by jurisdiction.

Regulatory Status

Canada (NPN)

Saffron extracts are recognized under the NHPID for natural health product use. Specific claim language depends on the monograph and the standardized extract being used. NPN submission is a standard pathway with documentation requirements around standardization and adulteration testing.

USA (DSHEA)

Sold as a dietary ingredient under DSHEA. Structure-function claims around mood and emotional well-being are common. Avoid disease-treatment language ("treats depression," "replaces antidepressants"). This is the highest-risk claim area for the ingredient.

Common Structure-Function Claims

  • Helps promote positive mood
  • Supports emotional well-being
  • Provides nutritional support for mental wellness
  • Helps support healthy appetite management

Claim language must be reviewed for your specific product and market before use. Not all claims are permitted in every jurisdiction.

Clinical Evidence & Market Demand

Selected peer-reviewed studies, plus the demand signals we're seeing from founders, retailers, and consumer search behaviour.

Primary literature

Market & consumer demand

Saffron supplement launches grew over 80% from 2022 to 2024 in DTC and clinical channels, driven by mood, ADHD, and natural-alternatives-to-SSRIs positioning.

Saffron sits in an interesting position: the clinical data is exceptional, but consumer awareness is still building outside of integrative-medicine circles. The brands winning here have been clinical-credibility plays. Affron-licensed mood products from companies like Pure Encapsulations and physician-targeted DTC startups. The largest growth signal in 2024–2025 is in the "natural alternative" mood space, particularly among consumers reluctant to start SSRIs but interested in evidence-based mood support. ADHD support is the second growth angle, particularly for parents seeking adjuncts or alternatives to stimulant medications for children. Both positioning angles require careful claim-language engineering to stay compliant.

  • Examine.com: Saffron: Rated as having strong evidence for depression and ADHD support, moderate for premenstrual symptoms and appetite. One of the highest-rated botanical mood actives.
  • Pharmactive Biotech (Affron®) clinical reference library: The supplier-maintained clinical study library that supports most premium saffron-mood product positioning. Useful for substantiation files and label claim cross-references.

References are provided for educational purposes. Citations do not constitute medical claims or guarantee outcomes. Structure-function claim language must be reviewed for your specific product and market.

Ready to build with Saffron Extract (Affron® / Satiereal®)?

Tell us about your product concept and we'll put together a formulation, sourcing, and manufacturing plan tailored to your brand, format, and market.